

## Trastuzumab ToGA

## PRELIMINARY SCORE

## CURATIVE



## NON-CURATIVE



## ADJUSTMENTS

## Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit



## Serious and disabling adverse effects



## Other adjustments



## Trastuzumab ToGA

## SCORE

## CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

## NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

## INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior anti-cancer treatment for their metastatic disease

Experimental Arm: Trastuzumab + ChT (cisplatin + capecitabine or 5-FU)

Control Arm: ChT



